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Efforts	 are	being	directed	 to	 systematically	 analyse	 the	non-coding	 genome	 for	 cancer-driving	
mutations1-6.	 Cis-regulatory	 elements	 (CREs)	 represent	 a	 highly	 enriched	 subset	 of	 the	 non-
coding	genome	in	which	to	search	for	such	mutations.	We	use	capture	Hi-C	for	19,023	promoter	
fragments	to	catalogue	the	regulatory	landscape	of	colorectal	cancer	(CRC)	in	cell	lines,	mapping	
CREs	 and	 integrating	 these	 with	 TCGA	 whole	 genome	 sequence	 and	 expression	 data7,8.	 We	
identify	 a	 recurrently	 mutated	 CRE	 interacting	 with	 the	 ETV1	 promoter	 affecting	 gene	
expression.	ETV1	expression	influences	cell	viability	and	is	associated	with	patient	survival.	We	
further	 refine	 our	 understanding	 of	 the	 regulatory	 effects	 of	 copy-number	 variations	 (CNVs),	
showing	RASL11A	 to	be	targeted	by	a	previously	 identified	enhancer	amplification1.	This	study	
reveals	 new	 insights	 into	 the	 complex	 genetic	 alterations	 driving	 tumour	 development,	
providing	a	paradigm	for	employing	chromosome	conformation	capture	to	decipher	non-coding	
CREs	relevant	to	cancer	biology.	
	
The	 identification	of	driver	mutations	as	distinguished	from	passenger	mutations	 is	 fundamental	
to	understanding	cancer	and	its	response	to	therapy.	With	the	large	number	of	exome-sequenced	
tumours,	all	genes	with	coding	changes	that	contribute	substantially	to	tumourigenesis	are	likely	
to	 be	 catalogued	 shortly.	 Motivated	 by	 the	 identification	 of	 recurrent	 mutations	 in	 regulatory	
elements	 in	 genes	 associated	with	 oncogenesis,	 such	 as	 the	TERT	 promoter9,10,	 and	TAL111	 and	
PAX512	enhancers,	efforts	are	now	being	directed	to	systematically	analyse	non-coding	regions	of	
cancer	genomes	for	driver	mutations1-6.	
	
Although	regional	excess	of	somatic	mutations	is	suggestive	of	positive	selection	in	tumours,	the	
size	 of	 the	 non-coding	 genome	 places	 a	 high	 burden	 on	 robustly	 establishing	 statistical	
significance.	Coding	regions	provide	obvious,	discrete	 intervals	 in	which	to	search	for	mutations,	
and	 it	 would	 be	 highly	 propitious	 to	 define	 similar	 functional	 elements	 for	 non-coding	 regions.	
CREs	modulating	gene	expression	represent	a	highly-enriched	subset	of	the	non-coding	genome	in	
which	to	search	for	driver	mutations.	These	CREs	however,	can	be	highly	tissue-specific,	are	often	
dispersed	 over	 long	 ranges,	 and	 only	 a	 small	 fraction	 of	 distal	 enhancers	 target	 the	 nearest	
transcript8,13.	 The	 recent	 development	 of	 high-throughput	 chromosome	 conformation	 capture	
techniques	 (Hi-C)	has	allowed	 researchers	 to	map	such	 regulatory	 regions,	and	 importantly,	 link	
these	to	their	respective	target	genes8,14-16.		
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Here	 we	 have	 used	 capture	 Hi-C	 (CHi-C)	 for	 19,023	 promoter	 fragments	 to	 catalogue	 the	 CRE	
landscape	of	CRC,	 identifying	putative	enhancers8,16.	Using	 these	data	 in	 conjunction	with	TCGA	
whole	 genome	 sequencing	 (WGS),	 RNA	 sequencing	 (RNAseq)	 and	 CNV	 data7,	 we	 report	 the	
identification	 of	 novel	 non-coding	 driver	 mutations	 for	 CRC	 (Fig.	 1,	 Supplementary	 Fig.	 1,	
Supplementary	Note).		
	
We	 prepared	 in	 situ	 HindIII-digested	 Hi-C	 libraries	 from	 CRC	 HT29	 and	 LoVo	 cell	 lines,	 which	
represent	 the	 two	 major	 molecular	 subtypes	 of	 CRC	 –	 microsatellite	 stable	 (MSS)	 and	
microsatellite	instable	(MSI),	respectively.	To	examine	the	interactions	underlying	CREs	in	CRC,	we	
generated	 a	 biotinylated	 RNA	 bait	 library,	 specifically	 targeting	 19,023	 promoter-encompassing	
HindIII	fragments	representing	2.3%	of	all	HindIII	fragments.	We	hybridised	in	situ	Hi-C	libraries	to	
the	RNA	baits	to	capture	promoter-associated	di-tags	and	sequenced	the	resulting	libraries,	from	
which	 we	 identified	 96,458	 and	 118,758	 significant	 contacts	 in	 LoVo	 and	 HT29	 respectively	
(Supplementary	 Tables	 1-3).	 In	 both	 cell	 lines,	 the	 majority	 of	 interactions	 were	 within	
topologically	 associated	 domains	 (TADs)	 (74%	 and	 83%	 in	 HT29	 and	 LoVo,	 respectively;	
Supplementary	Tables	4	and	5,	Supplementary	Note).	Across	127	cell	lines	and	tissues17	the	LoVo	
and	 HT29	 CREs	 showed	 strong	 enrichment	 of	 histone	 marks	 identified	 in	 colonic	 tissue	
(Supplementary	Table	6).	
	
The	 CREs	 identified	 by	 CHi-C	 were	 evolutionally	 conserved	 (P<1.0×10-3)	 and	 enriched	 for	
transcription	factor	(TF)	binding	as	compared	to	a	random	set	of	genomic	fragments	(3-fold	and	2-
fold	enrichment	for	HT29	and	LoVo	respectively,	P<1.0×10-3;	Supplementary	Fig.	2).	Based	on	the	
level	 of	 gene	 expression	 using	 RNAseq	 for	 respective	 target	 genes	we	 classified	 interactions	 as	
either	 active	 or	 inactive.	 As	 previously	 documented8,	 a	 higher	 frequency	 of	 interactions	 and	
shorter	 contact	 distances	 typified	 promoters	 of	 active	 genes	 (Supplementary	 Fig.	 3).	 For	 genes	
that	were	actively	transcribed,	both	promoters	and	their	respective	CREs	had	a	higher	number	of	
bound	TFs	(P<2.2×10-16;	Supplementary	Fig.	4).	Moreover,	a	relationship	between	elevated	gene	
expression	and	higher	proportion	of	TFs	bound	to	CREs	was	shown,	consistent	with	the	functional	
role	of	identified	CREs	(Supplementary	Fig.	5).		
	
To	investigate	the	frequency	of	single	nucleotide	variants	(SNVs)	 in	CREs	delineated	by	CHi-C	we	
analysed	colon	and	rectal	adenocarcinoma	WGS	data	from	TCGA7.	After	applying	stringent	quality	
control	and	filtering,	we	retained	data	on	50	MSS	and	12	MSI	cancers.	The	frequencies	of	SNV	base	
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changes	were	 consistent	with	 those	 previously	 documented	 for	 CRC18,19	 (Supplementary	 Fig.	 6,	
Supplementary	Table	7).	Both	promoters	and	CREs	showed	a	significantly	lower	rate	of	mutation	
compared	to	the	genome	rate	in	MSS	and	MSI	cancers	(Fig.	2).	This	property	was	also	seen	after	
taking	 into	 account	 mutational-signature-derived	 substitution	 probabilities	 (Fig.	 2).	 This	 is	
consistent	with	previous	reports	that	have	shown	that	functional	regulatory	regions	are	less	likely	
to	be	mutated	 than	non-functional	 regions	of	 the	genome,	either	as	a	consequence	of	 selective	
evolutionary	pressure	or	chromatin	accessibility9,20.	Since	MSI	cancers	exhibit	a	significantly	higher	
mutational	rate	to	MSS	cancers	(median	mutations	92,968	and	14,290,	respectively)	reflective	of	
mismatch	 repair	 deficiency19	 (Supplementary	 Table	 8),	 we	 analysed	 the	 two	 CRC	 subtypes	
separately.		
	
To	identify	non-coding	driver	mutations	in	CREs,	we	integrated	results	from	three	driver	discovery	
methods	(Supplementary	Fig.	7a).	First,	we	assessed	the	transcriptional	affects	of	CRE	mutations	
by	 comparing	 the	 expression	 levels	 of	 respective	 target	 genes	 in	 mutated	 and	 non-mutated	
cancers9,10,21.	To	avoid	confounding,	cancers	in	which	either	the	CRE	or	target	gene	were	subject	to	
CNVs	 were	 excluded	 from	 the	 analysis.	 Second,	 we	 tested	 for	 regional	 excess	 of	 mutations	 to	
provide	evidence	of	positive	selection6,9,21,22.	Third,	we	assessed	the	clustering	of	CRE	mutations,	
as	 this	 can	be	 suggestive	of	 events	 in	 specific	 TF	 binding	 sites21.	 In	MSS	 cancers	 this	 integrated	
analysis	yielded	a	CRE	interacting	with	the	ETV1	promoter,	associated	with	differential	target	gene	
expression	 and	 an	 excess	 of	 clustered	 mutations	 (Fig.	 3a-b,	 Supplementary	 Tables	 9	 and	 10).	
Conversely,	 no	 CREs	 were	 identified	 in	 MSI	 cancers,	 and	 we	 therefore	 restricted	 further	 SNV	
analysis	to	MSS	cancers.			
	
We	 demonstrated	 the	 benefit	 of	 using	 CHi-C	 data	 to	 discover	 non-coding	 driver	 mutations	 by	
comparing	the	number	of	CREs	identified	by	the	integrated	driver	discovery	analysis	using	real	and	
randomised	 CHi-C	 data.	 Specifically,	 we	 randomised	 the	 CHi-C	 data	 by	 changing	 the	 HindIII	
fragments	 contacting	 each	 gene,	 sampling	 from	 non-interacting	 fragments	 within	 1Mb	 of	 the	
gene,	whilst	maintaining	the	number	of	 fragment	contacts	 (Supplementary	Fig.	7b),	and	applied	
the	 integrated	 driver	 discovery	 analysis	 in	 full	 to	 each	 randomised	 CHi-C	 data	 set.	 Through	 this	
procedure	we	 estimated	 the	 empirical	 false	 discovery	 rate	 (FDR)	 for	 the	ETV1	CRE	 to	 be	 0.023	
(Supplementary	Table	9,	Supplementary	Fig.	8).		
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ETV1,	an	oncogene	encoding	an	ETS	TF,	 is	altered	 in	several	cancers	by	translocations	 in	Ewing's	
sarcoma23	and	prostate	cancer24,25,	amplification	 in	melanoma26,	and	oncogenic	dysregulation	 in	
gastrointestinal	stromal	tumours27,28.	The	ETV1	 interaction	was	confirmed	in	a	panel	of	MSS	CRC	
cell	 lines	(Supplementary	Fig.	9).	Considering	only	the	five	cancers	without	a	structural	variation	
(SV)	within	1	Mb	from	ETV1	(Supplementary	Table	11),	CRE	mutations	were	associated	with	a	4-
fold	 increased	 expression	 of	 ETV1	 compared	 to	 non-mutated	 samples	 (Fig.	 3b).	 Additionally,	
increased	ETV1	expression	was	also	seen	in	two	cancer	samples	without	CRE	mutations	but	with	
ETV1	 amplifications	 (P=4.1×10-3;	 Supplementary	 Fig.	 10a).	 Four	 of	 the	 six	 mutations	 map	
proximally	to	an	evolutionary	conserved	region	(Fig.	3a),	and	in	HT29	each	was	associated	with	a	
3-fold	 increase	 in	 luciferase	 activity,	 consistent	 with	 regulatory	 impact	 (Fig.	 3c,	 Supplementary	
Figure	10b).	The	ETV1	CRE,	which	is	proximal	to	an	enhancer	H3K4me1	chromatin	mark,	uniquely	
interacts	with	the	ETV1	promoter,	and	the	contact	is	not	present	in	LoVo	or	17	blood-specific	CHi-
C	data	 (Fig.	3a,	Supplementary	Fig.	11).	While	 the	putative	enhancer	maps	within	 the	 intron	of	
DGKB,	 there	was	 no	 relationship	 between	 CRE	mutation	 and	DGKB	 expression	 (Supplementary	
Fig.	12).	Although	no	TF	was	bound	to	the	CRE	on	the	basis	of	HT29	cell	line	ChIPseq	data,	in	silico	
analysis	 identified	 numerous	 potential	 disrupted	 TF	 binding	 sites29-31	 including	 those	 for	 BCL6,	
HNF1A,	HNF1B	and	MAFK,	all	of	which	are	expressed	in	colonic	tissue32	(Supplementary	Table	12	
and	13,	Supplementary	Fig.	13,	Supplementary	Note).		
	
We	 made	 use	 of	 Affymetrix	 SNP	 Array	 6.0	 data	 from	 615	 TCGA	 CRC	 samples	 to	 identify	 CREs	
subject	to	somatic	CNVs.	CNV-positive	CREs	were	assessed	for	correlation	with	expression	of	their	
interacting	gene,	where	it	was	not	encompassed	by	the	same	CNV,	using	matched	RNAseq	data.	
The	RASL11A	promoter	showed	interactions	with	a	putative	enhancer	characterised	by	H3K4me1	
marks	in	both	HT29	and	LoVo	cell	lines	(Fig.	4a,	Supplementary	Fig.	14).	While	a	role	for	RASL11A	
in	 tumourigenesis	 has	 yet	 to	 be	 defined,	 it	 is	 reported	 to	 be	 a	 GTPase	 chromatin-associated	
modulator	 of	 pre-ribosomal	RNA	 synthesis,	 acting	 to	 facilitate	 initiation	of	 transcription	by	RNA	
polymerase	 133.	 The	 RASL11A	 interaction	 was	 confirmed	 in	 a	 panel	 of	 MSS	 CRC	 cell	 lines	
(Supplementary	Fig.	9).	This	CRE	was	amplified	 in	12	cancer	samples	and	these	had	significantly	
higher	 RASL11A	 expression	 (P=2.96×10-11;	 Fig.	 4b,	 Supplementary	 Table	 14).	 Using	 CRISPR-
mediated	 genome	 editing,	 disruption	 of	 the	 interacting	 CRE	 was	 shown	 to	 reduce	 RASL11A	
expression	 (Fig.	 4c	and	 4d,	 Supplementary	 Fig.	 15).	USP12	 has	 previously	 been	 implicated	 as	 a	
target	of	this	specific	CRE1.	However,	after	exclusion	of	samples	 in	which	CNVs	overlay	the	gene	
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itself,	 amplification	 of	 the	 CRE	was	 not	 associated	with	 differential	 expression	 of	USP12	 or	 any	
other	gene	in	the	proximity	of	the	CNV	segments	(Fig.	4e,	Supplementary	Table	15).		
	
In	 HT29,	 reduction	 of	 endogenous	 ETV1	 and	 RASL11A	 levels	 using	 siRNA	 was	 associated	 with	
decreased	cell	viability	and	cell	proliferation	(Fig.	5,	Supplementary	Fig.	16,	Supplementary	Note).	
Using	 patient	 outcome	data	 from	 three	 independent	 series	 totalling	 1,282	 CRC	 cases7,34,35,	 high	
levels	 of	 ETV1	 expression	 were	 associated	 with	 worse	 relapse-free	 and	 overall	 survival	 in	 a	
multivariate	analysis.	Respective	meta-analysis	hazard	ratios	associated	with	elevated	expression	
were	 1.32	 (95%	 confidence	 interval	 [CI]:	 1.06-1.64,	 P=1.5×10-2)	 and	 1.14	 (95%	 CI:	 1.03-1.27,	
P=9.9×10-3)	 (Supplementary	 Fig.	 17,	 Supplementary	 Table	 16,	 Supplementary	 Note).	 No	
significant	 association	was	 shown	 between	RASL11A	 expression	 and	 patient	 outcome,	 although	
data	were	not	available	for	all	series	(Supplementary	Table	16).		
	
It	 is	arguable	that	despite	high-profile,	genuine	successes,	the	number	of	new	driver	genes	from	
exome	 sequencing	 projects	 has	 been	 disappointingly	 small	 compared	 with	 expectations.	 Many	
cancers	have	no	observable	driver	mutation,	and	the	full	complement	of	molecular	lesions	that	are	
individually	 necessary,	 and	 together	 sufficient,	 to	 cause	 malignancy	 are	 still	 unknown.	 The	
Encyclopedia	of	DNA	Elements	 (ENCODE)	project	has	proposed	 that	around	80%	of	 the	genome	
contains	elements	 linked	to	biochemical	functionality36,	however	others	have	estimated	that	the	
percentage	of	the	human	genome	that	is	functional	may	actually	be	10-fold	lower37.	Hence,	rather	
than	exploiting	the	epigenomic	landscape	we	identified	physical	contacts	between	promoters	and	
the	interacting	CREs,	thereby	reducing	the	genomic	space	in	which	to	search	for	non-coding	driver	
mutations.	
	
In	our	analysis,	we	identified	a	CRE	whose	mutation	was	associated	with	altered	expression	in	CRC.	
This	CRE,	interacting	with	the	ETV1	promoter,	was	mutated	in	12%	of	MSS	cancers	with	mutation	
being	associated	with	significant	upregulation	of	ETV1	expression.	While	not	previously	assessed	
as	 a	determinant	of	CRC	outcome38,	 upregulation	of	ETV1	was	 seen	 to	be	associated	with	poor	
patient	 prognosis	 in	 CRC	 (Supplementary	 Fig.	 17,	 Supplementary	 Table	 16).	 The	 fact	 that	
upregulation	 of	ETV1	 has	 previously	 been	 linked	 to	 reduced	 survival	 in	 other	 cancers,	 including	
gastric	cancer,	 is	 therefore	entirely	consistent	with	 increased	ETV1	expression	 inducing	aberrant	
activation	of	transcriptional	programs	that	generically	governs	multiple	facets	of	tumourigenesis.	
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In	addition	to	SNVs	having	a	role	in	dysregulation	of	gene	expression,	we	have	provided	evidence	
that	implicates	RASL11A,	through	amplification	of	an	interacting	CRE,	in	CRC	oncogenesis.		
	
We	acknowledge	that	the	present	analysis	has	limitations.	Firstly,	we	have	used	a	cellular	model	to	
map	the	CREs,	which	 is	unlikely	to	fully	recapitulate	the	spectrum	of	pathogenic	SNVs	and	CNVs	
seen	 in	 CRC.	 Secondly,	 the	 low-resolution	 of	 the	 defined	 CNVs	 has	 not	 permitted	 the	 study	 of	
smaller	 structural	 changes,	 potentially	 affecting	 the	 discovery	 of	 deleted	 or	 amplified	 CREs.	
Thirdly,	 inevitably	as	our	WGS	dataset	 is	modest,	 this	has	 restricted	 the	study	power	 to	 identify	
non-coding	drivers.	Fourthly,	our	strategy	may	not	identify	genes	that	are	up	or	down	regulated	in	
most	cancers,	either	when	driven	by	the	same	or	alternative	mechanisms.		
	
Accepting	these	caveats,	the	generation	of	a	genome-wide	promoter-CRE	map	of	CRC	using	in	situ	
CHi-C	has	allowed	us	to	perform	a	highly	focused	search	for	functional	non-coding	mutations.	As	
sequencing	 costs	 are	 significantly	 reduced,	 this	 will	 afford	 the	 opportunity	 to	 perform	 CHi-C	
directly	on	respective	WGS	samples,	thereby	providing	the	opportunities	to	define	individualised	
networks.		
	
In	conclusion,	our	work	supports	 the	existence	of	non-coding	drivers	 for	CRC,	and	more	broadly	
provides	a	paradigm	for	employing	chromosome	conformation	capture	to	decode	disease-specific	
regulatory	 elements.	 Such	 discoveries	 facilitate	 the	 identification	 of	 novel	 therapeutic	 and	
chemoprevention	 agents,	 and	 classification	 of	 patients	 into	molecular	 subgroups	 to	 personalise	
therapy.	 For	 example,	 it	 allows	 for	 the	 repositioning	 of	ETV1	 inhibitors,	 one	 of	which	 has	 been	
employed	in	a	clinical	trial	for	gastrointestinal	stromal	tumours28,39.		
	 	
	
	
Orlando	et	al	
8	
	
URLs	
SNPable,	 http://bit.ly/snpable;	 NCI	 Genomic	 Data	 Commons	 Data	 Portal,	
https://portal.gdc.cancer.gov/;	 UCSC	 Genome	 Browser,	
http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeUwRepliSeq/;	 GTex	
portal,	https://gtexportal.org/.	
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FIGURE	LEGENDS	
	
Figure	1.	Workflow	for	the	identification	of	mutated	cis-regulatory	elements	in	colorectal	cancer.	
CRE,	cis-regulatory	element;	SNV,	single	nucleotide	polymorphism;	CNV,	copy-number	variation.	
	
Figure	 2.	Non-coding	mutations	 in	 cis-regulatory	 elements.	Mutation	 rates	 in	 promoters,	 CREs	
and	 genome-wide	 in	 MSI	 (n=12)	 and	 MSS	 (n=50)	 cancers.	 Shown	 are	 both	 the	 mutation	 rates	
observed	in	promoters	and	CREs,	and	the	mutation	rates	expected	considering	the	sample-specific	
occurrence	of	mutations	of	each	of	the	96	substitution	types,	and	the	trinucleotide	composition	of	
the	 fragment	 classes.	 Box-plots	 denote	 quartiles.	 Whiskers	 correspond	 to	 the	 10th	 and	 90th	
percentiles.	Difference	assessed	using	a	two-sided	paired	Wilcoxon	test.		
	
Figure	 3.	 Cis-regulatory	 element	 mutation	 affects	 ETV1	 expression.	 (a)	 Chromatin	 looping	
interactions	between	the	ETV1	promoter	and	CREs	in	HT29.	Also	detailed	are	the	relative	positions	
of	 SNVs	 for	 the	 significantly	 mutated	 CRE	 and	 the	 evolutionary	 conservation	 of	 the	 region,	 as	
measured	 using	 PhastCons	 100-way	 smoothed	 scores	 and	 track.	 (b)	 Relationship	 between	
mutation	status	and	ETV1	expression	 in	MSS	cancers.	One	sample	containing	a	CNV	overlapping	
ETV1	 was	 excluded.	 Box-plots	 denote	 quartiles.	 Whiskers	 correspond	 to	 the	 10th	 and	 90th	
percentiles.	Difference	between	samples	in	which	the	CRE	is	mutated	(mut,	n=5)	and	not	mutated	
(non-mut,	n=41)	assessed	by	negative	binomial	test.	(c)	A	946bp	and	a	738bp	putative	regulatory	
regions	 containing	 the	 six	mutations	were	 cloned	 upstream	of	 the	 SV40	 promoter	 in	 the	 pGL3-
promoter	vector.	The	resultant	 reporter	constructs	were	 transiently	 transfected	 into	HT29	 for	24	
hours	 and	 the	 relative	 luciferase	 activity	 was	 measured	 for	 each	 reporter	 gene	 construct.	 The	
luminescence	 ratio	 of	 the	 experimental	 vector	 to	 the	 Renilla	 internal	 control,	 pRL-TK,	 was	
normalised	to	the	backbone	pGL3-SV40	promoter	vector.	Data	shown	are	mean	±	SEM	relative	to	
the	non-mutated	(Non	MUT)	samples	from	three	independent	experiments	and	assessed	by	two-
tailed	t-test,	n.s.,	non-significant.	
	
Figure	 4.	 Amplification	 of	 cis-regulatory	 element	 upregulates	 RASL11A	 expression.	 (a)	 The	
amplification	of	 the	CRE	 interacting	with	 the	RASL11A	promoter;	 upper	 track,	 CNVs	overlapping	
the	 CRE	 in	 12	 samples;	 middle	 track,	 H3K4me1	 mark	 in	 HT29	 and	 LoVo;	 lower	 track,	 CHi-C	
interactions	in	HT29	and	LoVo.	(b)	RASL11A	expression	in	CRC	stratified	by	CRE	amplification	status	
(samples	 with	 CNV	 overlapping	 RASL11A	 excluded).	 Box-plots	 denote	 quartiles.	 Whiskers	
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correspond	 to	 the	 10th	 and	 90th	 percentiles.	 Difference	 between	 samples	 in	 which	 the	 CRE	 is	
affected	 (CRE	 aff,	 n=12)	 and	 unaffected	 (CRE	 unf,	 n=522)	 by	 a	 CNV	 amplification	 assessed	 by	
negative	binomial	test.	 (c)	Schematic	representation	of	the	CRISPR/Cas9-mediated	deletion	using	
two	 plasmids	 expressing	 different	 sets	 of	 gRNAs.	 (d)	 Barplots	 showing	 RASL11A	 mRNA	 levels	
relative	 to	GAPDH	 in	 control	 (CTR)	 and	CRISPR-edited	 cells	 (CRISPR-1	and	CRISPR-2).	Differences	
assessed	 by	 two-tailed	 t-test	 from	 three	 independent	 experiments,	mean	 ±	 SEM.	 (e)	 Expression	
levels	of	 six	 genes	 in	 the	proximity	of	 the	CRE	 in	 the	 samples	where	 the	CRE	 is	 affected	 (aff)	or	
unaffected	(unf)	by	CNV	amplification	(RASL11A	unf	n=522,	RASL11A	aff	n=12,	USP12	unf	n=524,	
USP12	aff	n=7,	RPL21	unf	n=522,	RPL12	aff	n=12,	WASF3	unf	n=523,	WASF3	aff	n=14,	GTF3A	unf	
n=521,	GTF3A	aff	n=12,	GPR12	unf	n=523,	GPR12	aff	n=13).	Samples	containing	CNVs	overlapping	
the	 respective	 gene	 are	 excluded	 from	 each	 comparison.	 Box-plots	 denote	 quartiles.	 Whiskers	
correspond	to	the	10th	and	90th	percentiles.	Differences	assessed	by	negative	binomial	test,	 	n.s.,	
non-significant.		
	
Figure	 5.	 ETV1	 and	 RASL11A	 levels	 are	 associated	 with	 differential	 cell	 growth.	 (a)	 Relative	
luminescence	 of	 ETV1,	 RASL11A	 and	 control	 (CTR)	 knockdowns.	 Differences	 assessed	 72 hours	
post-transfection	 by	 two-tailed	 t-test	 using	 three	 independent	 experiments,	 mean	 ±	 SEM.	 (b)	
Relative	confluence	of	ETV1,	RASL11A	and	control	treated	cells.	Values	normalised	to	the	0	hour	
time-point	confluence.	Differences	assessed	96	hours	post-transfection	by	two-tailed	t-test	using	
three	 independent	 experiments,	 mean	 ±	 SEM.	 (c)	 Barplots	 showing	 ETV1	 and	 RASL11A	mRNA	
levels,	 normalised	 to	 GAPDH,	 after	 siRNA	 treatment.	 Differences	 assessed	 by	 two-tailed	 t-test	
using	three	independent	experiments,	mean	±	SEM.		
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ONLINE	METHODS	
	
Cell	culture		
HT115	and	SW948	were	obtained	from	ECACC,	and	all	other	cell	 lines	were	obtained	from	ATCC.	
All	 cell	 lines	 were	 cultured	 at	 37°C;	 LoVo	 was	 cultured	 in	 Ham's	 F-12	 Nutrient	 Mix,	 HT29	 was	
cultured	 in	McCoy's	 5A	 (Modified)	medium,	 SW480	 and	 SW1116	were	both	 cultured	 in	DMEM,	
SW948	were	cultured	 in	Leibovitz’s	L-15,	all	 supplemented	with	10%	FBS.	Caco2	was	cultured	 in	
MEM	supplemented	with	20%	FBS,	HT115	was	 cultured	 in	DMEM	supplemented	with	15%	FBS.	
Cell	 line	 identity	 was	 confirmed	 by	 STR-profiling.	 Cells	 were	 regularly	 tested	 for	 mycoplasma	
contamination	(PromoCell,	PK-CA91).	
	
Hi-C	analysis	
	
In	situ	Hi-C	library	preparation	
In	situ	Hi-C	libraries	were	prepared	as	previously	described14,16.	Briefly,	25	million	cells	were	fixed	
in	1%	formaldehyde	for	10	min.	Cross-linked	DNA	was	digested	by	restriction	enzyme	HindIII	(NEB,	
R0104).	 Digested	 chromatin	 ends	 were	 filled	 and	 marked	 with	 biotin-14-dATP	 (ThermoFisher,	
19524-016).	The	 resulting	blunted	ended	 fragments	were	 ligated	at	16°C	 in	 the	nucleus	with	T4	
DNA	 ligase	 (NEB,	 M0202)	 to	 minimise	 random	 ligation.	 DNA	 purified	 after	 crosslinking	 was	
reversed	by	proteinase	K	(Ambion,	AM2546)	treatment.	DNA	was	sheared	by	sonication	(Covaris,	
M220)	 and	 200-650bp	 fragments	 selected.	 Biotin	 tag	 DNA	 was	 pulled	 down	 with	 streptavidin	
beads	and	ligated	with	Illumina	paired	end	adapters	(Illumina).	Six	cycles	of	PCR	were	performed	
to	amplify	libraries	before	capture.		
	
Promoter	capture	Hi-C	library	
Promoter	 capture	 was	 based	 on	 32,313	 biotinylated	 120-mer	 RNA	 baits	 (Agilent	 Technologies)	
targeting	both	ends	of	HindIII	 restriction	 fragments	 that	overlap	Ensembl	promoters	of	protein-
coding,	non-coding,	antisense,	snRNA,	miRNA	and	snoRNA	transcripts8	(Supplementary	Table	17).	
After	 library	 enrichment,	 a	 post-capture	 PCR	 amplification	 step	 was	 carried	 out	 using	 5	
amplification	 cycles.	 Hi-C	 and	 CHi-C	 libraries	 were	 sequenced	 using	 HiSeq	 2000	 technology16	
(Illumina).		
	
Interaction	calling	
	
	
Orlando	et	al	
14	
	
Reads	were	aligned	to	the	GRCh37	build	using	Bowtie2	v2.2.640	and	identification	of	valid	di-tags	
was	performed	using	HiCUP	v0.5.941.	To	declare	significant	contacts,	HiCUP	output	was	processed	
using	CHiCAGO	v1.1.842.	For	each	cell	line,	data	from	three	independent	biological	replicates	were	
combined	to	obtain	a	definitive	set	of	contacts.	As	previously	advocated,	interactions	with	a	score	
≥5.0	were	considered	to	be	statistically	significant42.	
	
ChIPseq	analysis	
ChIPseq	 was	 performed	 on	 H3K4me1,	 H3K9me3,	 H3K27me3	 and	 H3K36me3	 for	 LoVo,	 and	
H3K4me1	and	H3K9me3	for	HT29.	Description	of	the	procedures	performed	can	be	found	in	the	
Supplementary	Note.		
	
Gene	expression	in	LoVo	and	HT29		
Analysis	 of	 RNAseq	 data	 on	 LoVo	 and	 HT29	 cell	 lines	 was	 performed	 as	 previously	 described7.	
Briefly,	RNAseq	BAM	files	were	downloaded	from	the	Broad	Institute	Cancer	Genomics	Hub	and	
analysed	 using	 Cufflinks43.	 Gene-level	 FPKM	 read	 counts	 were	 derived	 using	 GENCODE	 v7	
annotated	 mRNA	 transcripts.	 Genes	 with	 FPKM	 >0	 were	 divided	 into	 quartiles	 based	 on	 their	
expression	levels,	with	genes	with	either	0	FPKM	or	in	Q1	considered	to	be	inactive,	and	genes	in	
Q2-Q4	 considered	 to	 be	 active8,44.	 For	 promoter	 fragments	 associated	 with	 multiple	 genes,	 we	
excluded	those	with	discordant	expression.		
	
Annotation	of	cis-regulatory	elements	in	LoVo	and	HT29		
Reads	 that	 did	 not	 align	 uniquely	 were	 removed	 by	 HiCUP	 as	 they	 are	 liable	 to	 result	 in	 false	
positive	contacts.	The	detection	of	duplicate	 regions	 is	dictated	by	genomic	build.	Therefore,	an	
additional	 filtering	 step	 was	 performed	 to	 remove	 contacts	 between	 fragments	 mapping	 to	
regions	that	did	not	map	to	unique	locations	in	hg38.	Briefly,	hg19/GRCh37	was	split	into	windows	
of	100bp	before	being	aligned	to	hg38	using	BWA.	A	base	was	considered	to	be	poorly	mapped	if	
the	majority	of	reads	containing	 it	could	be	mapped	elsewhere	 in	the	genome	with	at	most	one	
mismatch	 or	 gap,	 as	 described	 in	 SNPable	 (see	 URLs).	 A	 contact	 region	 was	 kept	 if	 95%	 of	 its	
constituent	 bases	 were	 not	 poorly	 mapped	 imposing	 this	 metric.	 Conservation	 was	 measured	
using	PhastCons	100way,	considering	the	average	conservation	score	 in	100bp	windows	centred	
on	each	mutation45.	The	proportion	of	CREs,	not	overlapping	any	coding	regions,	containing	runs	
of	at	least	8	conserved	sites	(defined	by	PhastCons	score	>0.5)	was	compared	for	the	set	of	LoVo	
and	HT29	 CREs	 to	 sets	 of	 randomly	 generated	 fragments.	 For	 enrichment	 calculations,	 random	
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non-coding	 regions	of	 the	 genome	were	 selected	matching	 the	 identified	CREs	 in	 fragment	 size	
and	number,	restricting	start	positions	to	HindIII	sites.	Random	fragments	not	overlapping	coding	
regions	were	resampled	1,000	times.	Significance	was	determined	by	permutation.	We	annotated	
each	 CHi-C	 contact	 identified	 in	 LoVo	 and	 HT29	 cells	 with	 chromatin	 features	 and	 TF	 binding	
information.	HindIII	interacting	fragments	were	overlaid	with	histone	marks	from	127	tissues	and	
cell	 lines	 from	 the	 ROADMAP	 Epigenomics	 project17	 and	 ChIPseq	 experiments46	 (198	 and	 29	
experiments	 in	 LoVo	 and	 HT29	 respectively).	 Enrichment	 calculations	 were	 performed	 as	
described	above.	The	activity	of	each	promoter	on	its	corresponding	gene	was	defined	as	active	or	
inactive	 based	 on	 the	 analysis	 of	 the	 matching	 RNAseq	 data.	 To	 assess	 whether	 there	 was	 a	
relationship	between	TF	binding	and	expression,	we	selected	only	the	fragments	that	interact	with	
promoters	of	genes	belonging	to	the	same	expression	quartile	and	allocated	TF	counts	to	each	CRE	
as	 previously	 described8.	 For	 promoter	 fragments	 associated	 with	 multiple	 genes,	 all	 genes’	
expression	 was	 required	 to	 be	 in	 the	 same	 expression	 quartile.	 For	 each	 expression	 class,	 we	
calculated	the	proportion	of	CREs	bound	by	the	TF	divided	by	the	proportion	of	all	the	CREs	bound	
by	the	same	TF.	Corresponding	values	were	log2	transformed8,44.		
	
TCGA	colorectal	cancer	whole	genome	sequencing	data		
Whole-genome	 sequencing	 (WGS)	 data	 on	 50	 MSS	 (36	 colon	 adenocarcinoma	 [COAD]	 and	 14	
rectal	adenocarcinoma	[READ])	and	12	MSI	were	obtained	from	TCGA.	Description	of	these	data	
and	mutation	calling	can	be	found	in	the	Supplementary	Note.		
	
Mapping	non-coding	mutations	to	chromatin-looping	interactions		
We	mapped	non-coding	mutations	to	CREs	defined	by	promoter	CHi-C	generated	on	CRC	cell	lines,	
LoVo	and	HT29.	We	annotated	only	cis-interactions	involving	a	promoter	and	CRE,	excluding	trans-
interactions	and	promoter-promoter	contacts.	
	
Genome-wide	analysis	of	non-coding	mutations		
Mutations	were	allocated	to	promoters	or	CREs,	and	the	mutation	rates	for	each	fragment	class	
were	calculated.	Mutation	rates	were	determined	as	the	number	of	mutations	 in	each	fragment	
class,	divided	by	the	size	of	all	the	fragments	in	that	class,	minus	all	regions	overlapping	ORFs,	3’	
UTRs,	 5’	UTRs	 and	 regions	with	 poor	mappability	 (Supplementary	Note).	Mutational	 signatures	
have	 however	 been	 shown	 to	 be	 critical	 for	 estimating	 purifying	 selection	 pressures	 in	 cancer	
somatic	mutation	 data47.	 Taking	 this	 into	 account	 the	 expected	mutation	 rates	were	 estimated	
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considering	 the	 sample-specific	 occurrence	 of	 mutations	 of	 each	 of	 the	 96	 substitution	 types	
defined	by	Alexandrov	et	al.18,	and	the	trinucleotide	composition	of	the	fragment	class.		
Expected	mutation	rate = !!!! !!! ! 	! ∈ ( A[C>A]A,	…	,	T[T>G]T )	
where	i	is	each	of	the	possible	mutation	substitutions,	ui	is	the	genome-wide	number	of	mutations	
of	type	i,	vi	is	the	genome-wide	number	of	positions	at	which	mutations	of	type	i	can	occur,	wi	is	
the	number	of	positions	in	the	considered	fragment	class	at	which	mutations	of	type	i	can	occur,	
and	 y	 is	 the	 size	 of	 all	 fragments	 in	 the	 class.	 Excluded	 regions	 as	 defined	 above	 were	 not	
considered.		
	
Integrated	analysis	of	non-coding	mutations	in	CREs	
To	 identify	potential	non-coding	driver	mutations	we	 integrated	 three	driver	discovery	methods	
(Supplementary	Fig.	7a).	 In	this	 integrated	analysis,	we	(i)	assessed	the	transcriptional	effects	of	
non-coding	mutations	 in	CREs,	 and	 (ii)	 tested	 for	an	excess	of	non-coding	mutations	 in	CREs.	P-
values	 computed	 in	 these	 two	 analyses	were	 adjusted	 for	multiple	 testing	 using	 the	Benjamini-
Hochberg	procedure	and	CREs	excluded	 if	Q≥0.05	 in	either	analysis.	 Finally	we	 (iii)	 assessed	 the	
clustering	 of	 non-coding	mutations	 in	 the	 remaining	 CREs.	P-values	 computed	 in	 this	 clustering	
analysis	 were	 adjusted	 for	 multiple	 testing	 using	 the	 Benjamini-Hochberg	 procedure	 and	 CREs	
excluded	if	Q≥0.05.	These	three	driver	discovery	methods	are	outlined	below.		
	
Testing	the	transcriptional	effects	of	non-coding	mutations	in	CREs	
Gene	 expression	 profiles	 were	 based	 on	 RNA	 sequencing	 of	 12	 MSI	 and	 50	 MSS	 CRC	 cases	
obtained	 from	 TCGA	 that	 had	 matched	 WGS	 data	 (normalised	 gene-level	 values,	 accessed	 20	
January	2017).	Differences	between	samples	analysed	on	Genome	Analyzer	and	HiSeq	were	batch-
corrected	 using	 the	 ComBat	 method48.	 To	 reduce	 spurious	 long	 distance	 contacts,	 interactions	
were	 filtered	such	that	 the	distance	between	the	promoter	and	CRE	was	<1Mb49.	For	each	CRE,	
samples	were	divided	between	non-mutated	and	mutated	based	on	the	presence	of	non-coding	
mutations	in	the	corresponding	CRE.	We	tested	for	differential	gene	expression	between	mutated	
and	non-mutated	groups	using	a	negative	binomial	model9,	implemented	in	edgeR50.	Samples	with	
copy	 number	 alterations	 at	 either	 the	 gene	 or	 the	 related	 CRE	were	 excluded9.	 CREs	were	 not	
tested	 if	 gene	 expression	 data	 were	 not	 available	 for	 the	 interacting	 gene,	 or	 if	 the	 CRE	 was	
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mutated	in	fewer	than	two	samples,	after	the	removal	of	samples	with	overlapping	copy	number	
alterations.	CREs	observed	to	interact	with	the	promoters	of	multiple	genes	were	tested	multiple	
times.	Only	CREs	interacting	with	protein-coding	genes	were	tested.		
	
Testing	for	an	excess	of	non-coding	mutations	in	CREs	
We	tested	regions	for	an	excess	of	non-coding	mutations	using	a	global	approach,	as	per	Weinhold	
et	al9.	This	assumes	that	the	observed	number	of	tumour	samples	mutated	in	any	specific	region	
follows	the	binomial	distribution,	under	the	null	hypothesis	that	mutations	 in	the	region	are	not	
under	positive	selection.	As	replication	timing	affects	the	nucleotide	mutation	rate,	we	estimated	
the	mutation	rate	using	data	from	HeLa,	K562,	HEPG2,	MCF7	and	SKNSH	cell	lines51.	Again	as	per	
Weinhold	et	al.9,	we	subsetted	the	genome	into	100kb	bins	and	derived	mean	replication	times	for	
each	cell	line	across	each	bin.	For	each	interacting	region,	we	then	computed	a	single	replication	
time	for	each	cell	line	by	taking	the	replication	time	of	the	100kb	bin	in	which	the	region	is	located,	
or	 the	 average	 replication	 time	 if	 the	 region	 spanned	multiple	 100kb	 bins.	 For	 each	 interacting	
region,	we	then	identified	the	top	5%	of	interacting	regions	with	the	most	similar	replication	times	
across	 cell	 lines,	 measured	 using	 the	 Euclidian	 distance	 between	 the	 vectors	 of	 times.	 The	
background	 nucleotide	 mutation	 rate	 qi	 could	 then	 be	 estimated	 by	 dividing	 the	 number	 of	
mutations	in	this	5%	of	interacting	regions	across	all	samples	by	the	total	number	of	samples	with	
mutation	 data	 and	 the	 total	 effective	 length	 of	 the	 regions.	 These	 results	 are	 robust	 to	 the	
percentage	of	interacting	regions	considered	(Supplementary	Table	18).	We	excluded	the	areas	of	
the	 interacting	 regions	 overlapping	 ORFs,	 3’	 UTRs,	 5’	 UTRs	 and	 areas	 with	 poor	 mappability	
(Supplementary	Note).	The	removal	of	these	areas	is	incorporated	into	the	effective	lengths	of	the	
regions.	 The	 estimated	 sample	 mutation	 rate	 si	 is	 dependent	 on	 the	 estimated	 nucleotide	
mutation	rate	qi	of	the	region	under	the	null	hypothesis,	and	the	effective	size	of	the	region	Li:	
	 !! =  1− 1− !! !! .	
	
Mutational	excess	P-values	follow	discreet	distributions	and	we	therefore	computed	randomised	
P-values	for	each	region	i	using	the	right	tail	masses,	as	per	Imielinski	et	al22:		
	
!! = ! ! ≥ ! = 1− !! !!!(1− !!)!!!!!!!!! 	
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!! = ! ! ≥ ! + 1 = 1− !! !!!(1− !!)!!!!!!! 	!!  ~ !"#$%&' !! ,!! 	
	
where	n	is	the	total	number	of	cancers,	k	the	number	of	cancers	with	≥	1	mutation	in	region	i	and	
pi	 is	 the	 corresponding	 randomised	P-value.	 Inflation	 factor	 estimation	was	 conducted	with	 the	
regression	method	implemented	in	the	GenABEL	R-package52.	Using	all	P-values	indicated	that	the	
statistics	generated	under	this	model	are	weakly	inflated	(λ100%=1.08;	Supplementary	Fig.	18).	
	
Testing	for	clustering	of	non-coding	mutations	in	CREs	
We	 evaluated	 whether	 CRE	 mutations	 cluster	 using	 the	 weighted	 average	 proximity	 (WAP)	
method21:	
	
WAP = !!(!!,!!!!!)!!! 	
	
where	d	is	the	linear	genomic	distance	between	mutations	i	and	j,	and	t	is	a	weighting	constant.	As	
per	Rheinbay	et	al.21,	we	used	t=6,	as	this	reflects	the	typical	size	of	the	core	of	TF	binding	motifs.	
Statistical	significance	of	each	WAP	score	was	determined	by	permuting	mutation	positions	10,000	
times,	whilst	maintaining	the	size	of	the	CRE	and	excluding	regions	overlapping	ORFs,	3’	UTRs,	5’	
UTRs	 and	 regions	 with	 poor	 mappability	 (Supplementary	 Note).	 Empirical	 P-values	 were	
calculated	as	 the	proportion	of	mutation	permutations	with	WAP	scores	at	 least	as	great	as	 the	
WAP	score	computed	using	the	observed	mutation	positions.	
	
Empirical	FDR	estimation	
We	estimate	an	empirical	FDR	for	the	identified	CRE	by	comparing	the	number	of	results	yielded	
by	 the	 integrated	 driver	 discovery	 analysis	 when	 using	 real	 and	 randomised	 CHi-C	 data	
(Supplementary	 Fig.	 7b).	 CHi-C	 data	 were	 randomised	 by	 changing	 the	 HindIII	 fragments	
contacting	 each	 gene,	 by	 sampling	 from	 non-interacting	 fragments	 (CHiCAGO	 score	 <1)	 within	
1Mb	 of	 the	 gene,	 whilst	 maintaining	 the	 number	 of	 fragment	 contacts.	 The	 integrated	 driver	
discovery	 analysis	 was	 then	 applied	 in	 full	 to	 each	 randomised	 CHi-C	 data	 set.	 The	 expected	
number	of	false	discoveries	was	estimated	as	the	mean	number	of	CREs	yielded	by	the	integrated	
driver	 discovery	 analysis	 across	 1,000	 randomised	 CHi-C	 data	 sets.	 The	 empirical	 FDR	 was	
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estimated	as	the	ratio	of	false	discoveries	to	the	total	number	of	CREs	detected	when	the	real	CHi-
C	data	were	used53.		
	
Relationship	between	gene	expression	and	CNV	at	CREs	
To	 identify	 CNVs	 overlapping	 CREs,	we	 utilised	 Affymetrix	 Genome-Wide	Human	 SNP	 Array	 6.0	
copy	number	data	from	the	TCGA	COAD	study	of	450	cancers	and	the	READ	study	of	165	cancers.	
Focal	 deletions	 and	 amplifications	 were	 defined	 as	 abs(log2ratio)	 ≥0.354	 and	 size	 <3Mb55.	 We	
analysed	matched	RSEM	RNAseq	and	CNV	data	from	the	TCGA	COAD	and	READ	studies	(n=606).	
To	 identify	 cancers	with	 deleted	 or	 amplified	 CREs	 correlated	with	 expression	 of	 an	 interacting	
gene,	we	applied	the	following	filters	to	each	CRE-promoter	interaction:	(i)	we	identified	cancers	
with	a	focal	amplification	or	deletion	of	the	CRE;	(ii)	we	excluded	cancers	with	evidence	of	a	CNV	
at	the	interacting	gene	(a	GISTIC2	score	≠0);	(iii)	we	restricted	our	analysis	to	CREs	affected	in	≥7	
samples	 (representing	 1%	 of	 samples).	 We	 compared	 gene	 expression	 between	 affected	 and	
unaffected	samples	using	edgeR50	with	default	parameters.	Samples	were	considered	unaffected	if	
there	was	no	evidence	of	a	CNV	at	the	CRE	(a	GISTIC2	score	=0).	Genes	that	showed	differential	
expression	between	affected	and	unaffected	samples	and	an	absolute	correlation	coefficient	≥0.4	
between	GISTIC2	score	and	gene	expression	value	were	taken	forward	for	further	analysis.	
	
Relationship	between	CRE	mutation	and	translocations	and	inversions	
Since	 translocations	 and	 inversions	 can	 dysregulate	 gene	 expression	 we	 examined	 for	
translocations	 and	 inversions	 in	 the	 proximity	 of	 mutated	 CRE	 target	 genes.	 Translocation	 and	
inversion	 breakpoints,	 called	 using	 dRanger56,	 were	 downloaded	 from	 the	 International	 Cancer	
Genomic	Consortium	Data	Portal	(accessed	30	July	2017).	
	
Genomic	DNA	extraction		
Cells	were	 collected,	washed	 twice	 in	 PBS	 and	 genomic	DNA	was	 extracted	 using	QIAamp	DNA	
Blood	 Mini	 Kit	 (Qiagen).	 DNA	 concentration	 was	 measured	 using	 Qubit	 dsDNA	 BR	 Assay	
(ThermoFisher	Scientific).	
	
3C-PCR	validation	
3C	was	used	to	validate	ETV1	and	RASL11A	 interactions	in	a	panel	of	colon	derived	MSS	CRC	cell	
lines.	Two	cell	culture	replicates	of	in	situ	3C	libraries	were	prepared	using	HT29,	SW480,	SW1116,	
Caco2,	HT115	and	 SW948	 cells.	 Cell	 pellets	were	 cross-linked,	 digested	with	HindIII,	 and	 ligated	
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using	the	same	conditions	described	in	the	Hi-C	section,	excluding	the	biotin	step.	Digestion	and	
ligation	 efficiency	 were	 assessed	 on	 agarose	 gel	 before	 proceeding	 to	 phenol-chloroform	
purification.	 Ligation	 primer	 pairs	 were	 designed	 to	 amplify	 ligation	 junctions	 between	 the	
promoter	 and	 interacting	 HindIII	 fragment	 (promoter-CRE)	 (Supplementary	 Table	 19).	 Genomic	
DNA	was	used	as	control	for	the	possibility	that	amplification	across	ligation	junctions	could	be	the	
result	 of	 structural	 variations.	 To	prove	 fidelity	of	 genomic	DNA	as	 template,	 primer	pairs	were	
also	designed	to	amplify	the	genomic	region	around	each	of	the	ligation	primers	(Supplementary	
Table	19).	All	primers	were	designed	using	Primer3.	Regions	were	amplified	using	Multiplex	PCR	
Kit	 (Qiagen);	 100ng	 template	 DNA	 amplified	 using	 the	 following	 procedure:	 initial	 15	 min	
denaturation	at	95°C	followed	by	38	cycles	of	95°C	for	30	seconds,	60°C	for	90	seconds,	72°C	for	
45	 seconds.	 5μl	 of	 each	 PCR	 reaction	was	 visualised	 on	 2%	 agarose	 gels	 stained	with	 ethidium	
bromide.	 Identity	 of	 fragments	 visualised	 on	 agarose	 gels	was	 confirmed	 by	 Sanger	 sequencing	
(Supplementary	Fig.	9).	
	
Plasmid	construction	and	luciferase	assays		
The	 length	 of	 the	 full	 region	 spanning	 the	 six	 mutations	 is	 over	 1.2kb	 and	 therefore	 a	 1.6kb	
fragment	 would	 have	 been	 required	 to	 ensure	 that	 all	 mutations	 mapped	 centrally	 within	 the	
fragment.	In	view	of	this	we	decided	to	clone	the	two	fragments	separately,	so	as	to	have	cloned	
inserts	 <1kb.	 A	 946bp	 and	 a	 738bp	 genomic	 region	 within	 the	 ETV1	 CRE	 were	 amplified	 from	
human	 genomic	 DNA	 using	 primers	 detailed	 in	 Supplementary	 Table	 19.	 Gel-purified	 PCR	
products	(Qiagen)	were	A-tailed	using	2U	Thermoprime	DNA	polymerase	(ThermoFisher	Scientific)	
and	200µM	dATP	for	30	min	at	70°C.	The	products	were	cloned	into	the	PCR8/GW/TOPO	vector	
and	single	bacterial	colonies	containing	the	vector	were	cultured	and	purified	(Qiagen	Mini-prep	
Kit).	 The	 six	 somatic	 mutations	 were	 generated	 with	 site-directed	 mutagenesis	 (SDM)	 (Agilent	
Quick	 Change	 XL	 kit)	 using	 primers	 detailed	 in	 Supplementary	 Table	 19.	 SDM	 changes	 were	
confirmed	 by	 Sanger-sequencing.	 Regulatory	 regions	 with	 both	 non-mutated	 and	 mutated	
sequences	were	 cloned	 into	 pGL3	 luc2-promoter	 vector	 (Promega)	 using	Gateway	 LR	 Clonase	 II	
technology	 (ThermoFisher	 Scientific).	 The	 reporter	 constructs	were	 transfected	 into	 HT29	 using	
Lipofectamine	2000	 (ThermoFisher	Scientific).	Briefly,	7.5×105 cells	were	 seeded	and	 transfected	
the	 following	 day	with	 3μg	 reporter	 constructs	 and	 150ng	 of	 internal	 control	 plasmid	 (pRL-TK).	
Transiently	transfected	cells	were	cultured	for	24	hours,	following	which	the	luciferase	assay	was	
performed	 using	 the	 Dual-Luciferase	 Reporter	 Assay	 System	 (Promega)	 as	 per	 manufacturer's	
recommendations.	 Firefly	 and	 Renilla	 luciferase	 luminescence	were	measured	 in	 triplicate	 on	 a	
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Fluoroskan	Ascent	FL	plate	 reader	 (ThermoFisher	Scientific).	The	 ratio	of	 luminescence	 from	the	
experimental	 reporter	 to	 the	 luminescence	 from	 the	 control	 reporter	 was	 calculated	 for	 each	
sample,	defined	as	the	relative	luciferase	activity.	
	
CRISPR-Cas9-mediated	enhancer	disruption	
Two	 set	 of	 guide	 RNAs	 (gRNAs)	were	 designed	 to	 target	 the	 CRE	 interacting	with	 the	RASL11A	
promoter	using	E-CRISP57.	To	check	that	the	required	PAM	sequence	was	not	altered	in	the	HT29	
cell	 line,	 the	 region	where	 the	gRNAs	were	mapped	was	Sanger-sequenced	using	genomic	DNA.	
Each	set	of	gRNAs	was	designed	to	target	upstream	and	downstream	of	the	enhancer	region,	and	
cloned	 in	 one	 plasmid	 expressing	 the	 Cas9	 gene	 and	 the	 RFP-marker.	 A	 control	 plasmid	 was	
generated	 containing	 all	 the	 elements	 of	 the	 targeting	 plasmids	 other	 than	 the	 gRNAs.	 Custom	
plasmids	were	obtained	 from	ATUM.	gRNA	sequences	are	 reported	 in	Supplementary	Table	19.	
HT29	were	seeded	at	7.5x105	density	in	6-well	plates	and	transfected	the	following	day	with	10µl	
of	 Lipofectamine	 2000	 (ThermoFisher	 Scientific)	 and	 2µg	 of	 the	 respective	 plasmids.	 48	 hours	
post-transfection	cells	expressing	RFP	were	selected	and	seeded	into	using	FACSAriaIIμ	cell	sorter	
(BD	Biosciences)	in	a	24-well	plate.	After	2-3	weeks	cells	were	harvested	to	extract	either	genomic	
DNA	to	confirm	the	enhancer	deletion,	or	 total	RNA	to	assess	gene	expression.	Primers	used	 to	
assess	the	deletion	are	listed	in	Supplementary	Table	19.	
	
Cell	viability	assays	
In	 96-well	 plates,	 cells	 were	 transfected	with	 siRNAs	 and	 incubated	with	 Cell	 Titer	 Glo	 reagent	
according	 to	 the	 manufacturer's	 protocol	 (Cell	 Titer	 Glo	 Luminescent	 Cell	 Viability	 Assay	 kit,	
Promega).	For	each	experiment,	luminescence	was	measured	in	triplicate	at	0,	24,	48	and	72	hours	
post-transfection	 using	 a	 Fluoroskan	 Ascent	 FL	 plate	 reader	 (ThermoFisher	 Scientific)	
(Supplementary	Fig.	16).		
	
Real-time	cell	proliferation	assays	
After	 RNAi	 transfection,	 96-well	 plates	were	 introduced	 into	 an	 Incucyte	 Zoom	 imaging	 system	
(Essen	 BioScience)	 enclosed	 in	 an	 incubator	 at	 37°C	 and	 5%	 CO2	 humidified	 air.	 Each	well	was	
imaged	 by	 phase	 contrast	 every	 four	 hours	 for	 92	 hours.	 Images	 were	 collected	 and	 the	
percentage	of	confluence	determined	using	software	provided	by	 the	manufacturer.	Confluence	
was	averaged	over	four	fields	of	view	per	well.	Data	were	normalised	to	the	first	scan	to	account	
for	differences	in	seeding	across	individual	samples	and	across	replicates.	
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Statistical	analyses	
The	 observed	 and	 expected	mutation	 rates	 in	 promoters	 and	 CREs	 were	 compared	 using	 two-
sided	paired	Wilcoxon	 tests.	CHi-C	 interactions	 involving	promoters	of	active	and	 inactive	genes	
were	 compared	 using	 two-sided	Wilcoxon	 tests8.	 For	 luciferase,	 cell	 viability	 and	 real-time	 cell	
proliferation	 assays,	 statistical	 significance	 was	 calculated	 using	 two-tailed	 t-tests	 over	 three	
independent	 experiments.	 The	 Benjamini-Hochberg	 procedure	 was	 used	 to	 adjust	 for	 multiple	
testing,	unless	otherwise	specified.	
	
Reporting	summary	
Further	 information	 on	 our	 experimental	 design	 is	 available	 in	 the	 Nature	 Research	 Reporting	
Summary	document	linked	to	this	article.		
	
DATA	AVAILIBILITY		
Hi-C,	CHi-C,	and	histone	ChIPseq	sequencing	data	have	been	deposited	in	the	European	Genome-
phenome	 Archive	 (EGA)	 under	 the	 accession	 code	 EGAS00001001946.	WGS,	 RNAseq,	 CNV	 and	
survival	 data	 for	 TCGA	 COAD	 and	 READ	 samples,	 and	 RNAseq	 data	 for	 HT29	 and	 LoVo	 (CCLE	
program)	were	obtained	from	the	NCI	Genomic	Data	Commons	Data	Portal	(see	URLs).	TF	ChIPseq	
data	 were	 obtained	 from	 the	 Gene	 Expression	 Omnibus	 (GEO)	 (GSE49402).	 Survival	 data	 were	
obtained	 from	GEO	 (GSE33113,	GSE39582).	 Replication	 timing	 data	were	 downloaded	 from	 the	
UCSC	Genome	Browser	 (see	URLs).	GTEx	 data	 (release	 v6)	were	 obtained	 from	 the	GTex	 portal	
(see	URLs).	
	
	
	 	
	
	
Orlando	et	al	
23	
	
METHODS-ONLY	REFERENCES	
	
40.	 Langmead,	 B.	&	 Salzberg,	 S.L.	 Fast	 gapped-read	 alignment	with	 Bowtie	 2.	Nat	Methods	9,	 357-9	
(2012).	
41.	 Wingett,	S.	et	al.	HiCUP:	pipeline	for	mapping	and	processing	Hi-C	data.	F1000Res	4,	1310	(2015).	
42.	 Cairns,	 J.	 et	 al.	 CHiCAGO:	 robust	 detection	 of	 DNA	 looping	 interactions	 in	 Capture	 Hi-C	 data.	
Genome	Biol	17,	127	(2016).	
43.	 Trapnell,	 C.	 et	 al.	 Transcript	 assembly	 and	 quantification	 by	 RNA-Seq	 reveals	 unannotated	
transcripts	and	isoform	switching	during	cell	differentiation.	Nat	Biotechnol	28,	511-5	(2010).	
44.	 Schoenfelder,	S.	et	al.	The	pluripotent	regulatory	circuitry	connecting	promoters	to	their	long-range	
interacting	elements.	Genome	Res	25,	582-97	(2015).	
45.	 Pollard,	K.S.,	Hubisz,	M.J.,	Rosenbloom,	K.R.	&	Siepel,	A.	Detection	of	nonneutral	substitution	rates	
on	mammalian	phylogenies.	Genome	Res	20,	110-21	(2010).	
46.	 Yan,	 J.	 et	 al.	 Transcription	 factor	 binding	 in	 human	 cells	 occurs	 in	 dense	 clusters	 formed	 around	
cohesin	anchor	sites.	Cell	154,	801-13	(2013).	
47.	 Van	 den	 Eynden,	 J.	 &	 Larsson,	 E.	 Mutational	 Signatures	 Are	 Critical	 for	 Proper	 Estimation	 of	
Purifying	Selection	Pressures	in	Cancer	Somatic	Mutation	Data	When	Using	the	dN/dS	Metric.	Front	
Genet	8,	74	(2017).	
48.	 Johnson,	W.E.,	 Li,	 C.	&	 Rabinovic,	 A.	 Adjusting	 batch	 effects	 in	microarray	 expression	 data	 using	
empirical	Bayes	methods.	Biostatistics	8,	118-27	(2007).	
49.	 Grubert,	 F.	 et	 al.	 Genetic	 Control	 of	 Chromatin	 States	 in	 Humans	 Involves	 Local	 and	 Distal	
Chromosomal	Interactions.	Cell	162,	1051-65	(2015).	
50.	 Robinson,	 M.D.,	 McCarthy,	 D.J.	 &	 Smyth,	 G.K.	 edgeR:	 a	 Bioconductor	 package	 for	 differential	
expression	analysis	of	digital	gene	expression	data.	Bioinformatics	26,	139-40	(2010).	
51.	 Hansen,	 R.S.	 et	 al.	 Sequencing	 newly	 replicated	 DNA	 reveals	 widespread	 plasticity	 in	 human	
replication	timing.	Proc	Natl	Acad	Sci	U	S	A	107,	139-44	(2010).	
52.	 Aulchenko,	 Y.S.,	 Ripke,	 S.,	 Isaacs,	 A.	 &	 van	 Duijn,	 C.M.	 GenABEL:	 an	 R	 library	 for	 genome-wide	
association	analysis.	Bioinformatics	23,	1294-6	(2007).	
53.	 Carter,	H.	et	al.	 Interaction	Landscape	of	Inherited	Polymorphisms	with	Somatic	Events	 in	Cancer.	
Cancer	Discov	7,	410-423	(2017).	
54.	 Mermel,	C.H.	et	al.	GISTIC2.0	facilitates	sensitive	and	confident	 localization	of	the	targets	of	 focal	
somatic	copy-number	alteration	in	human	cancers.	Genome	Biol	12,	R41	(2011).	
55.	 Litchfield,	K.	et	al.	Whole-exome	sequencing	reveals	the	mutational	spectrum	of	testicular	germ	cell	
tumours.	Nat	Commun	6,	5973	(2015).	
56.	 Drier,	 Y.	 et	 al.	 Somatic	 rearrangements	 across	 cancer	 reveal	 classes	 of	 samples	 with	 distinct	
patterns	 of	 DNA	 breakage	 and	 rearrangement-induced	 hypermutability.	Genome	 Res	 23,	 228-35	
(2013).	
57.	 Heigwer,	F.,	Kerr,	G.	&	Boutros,	M.	E-CRISP:	fast	CRISPR	target	site	identification.	Nat	Methods	11,	
122-3	(2014).	
	
